# A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

> **NCT00942162** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 125 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Immunotherapeutic GSK2132231A

## Key facts

- **NCT ID:** NCT00942162
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-14
- **Primary completion:** 2012-06-27
- **Final completion:** 2015-04-01
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00942162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00942162, "A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00942162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*